Merck news from FierceBiotech
NewsMerck, Schering-Plough end respiratory collaboration
Merck and Schering-Plough have withdrawn their NDA for a pill combining Claritin and Singulair and are breaking up their respiratory collaboration, which has been in place since 2000. The goal of the Read more...
Study projects new wave of globalization in biopharma
Don't be misguided by dated reports discounting the impact Indian and Chinese scientists are having in drug development and other key technologies, says a new study from Duke and Harvard. Looking at Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
Merck's osteoporosis drug performs in Phase II
Merck's experimental osteoporosis drug odanacatib turned in positive results in a Phase II trial. The drug reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast Read more...
Amgen's D-mab beats Fosamax in trial
In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Read more...
Merck shelves study of cholesterol drug
Saying it had the wrong patient population, Merck has discontinued its ACHIEVE imaging study for its cholesterol drug MK-0524A. Its steering committee recommended a new imaging study that included a Read more...
Biotech entrepreneurs grow a new CRO in China
Biotech entrepreneur John Oyler--who helped found Genta and Galanea--sat down with Chemistry World to discuss his three-year-old Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
Merck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
| Press ReleasesCelera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets /10/2008 ALAMEDA, Calif. -- Celera, an Applera Corporation business, today announced a two year exclusive Read more... Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose Read more... Merck Sells Pennsylvania Chemicals Plant Merck Sells Pennsylvania Chemicals Plant PHILADELPHIA, Jan. 1 -- PRWT Services, Inc., a minority-owned business enterprise, today announced that it has, through its wholly-owned subsidiary, Cherokee Read more... PRESS RELEASE: Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal CAMBRIDGE, Mass. -- Idera Pharmaceuticals announced today that it has entered into a worldwide licensing and collaboration Read more... PRESS RELEASE: Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX WHITEHOUSE STATION, N.J., Dec. 12, 2007 - Merck & Co., Inc. announced today that the Company has initiated a voluntary Read more... |
Get more Merck coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends